OakChart

Orthofix Medical Inc

OFIXHealthcare·Medical Devices·USA·Micro·NASD·Nov 11 • 10:44 AM ET

7.30+0.18 (2.46%)
2026-11-11 16:44 CET
Market cap
290.02 USD m
Revenue, TTM
835.41 USD m
Net income, TTM
-45.00 USD m
Free cash flow, TTM
-43.11 USD m
EPS diluted, TTM
-1.11
P/E
-
Compare

Price

OFIX against its 20, 50 and 200-day averages
2050200beat
8.0010.0012.0014.001.3M2.7MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26OFIXclose 7.3020-day 9.1650-day 9.17200-day 10.887.3052w low

55.6% under the 52-week high of 16.42 on 8 Jan 2026. 52-week low 6.52 on 9 Nov 2026. Last 15 sessions, 62.1% high to low

Profile

OFIX
52-week range, 8% of the way up
6.5216.42

Orthofix Medical, Inc. develops and markets medical devices and biologic solutions for spine and orthopedic applications. The company operates through two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers two primary product categories: Bone Growth Therapies and Spinal Implants, Biologics, and Enabling Technologies. Bone Growth Therapies includes noninvasive stimulation devices used in spinal fusion and fracture-healing applications. Spinal Implants, Biologics, and Enabling Technologies includes a broad portfolio of spine fixation and motion-preservation products, biologic solutions, and image-guided surgical technologies used in spine procedures. The Global Limb Reconstruction segment provides products and solutions for limb reconstruction, deformity correction, fracture management, and other orthopedic conditions unrelated to the spine. The company was founded on October 19, 1987 and is headquartered in Lewisville, TX.

IndexRUT
Employees1605
IPOApr 24, 1992
Beta0.67
ATR, 14d0.65
Rel volume0.85
Short float5.40%
Insider own1.21%
Inst own94.98%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap297.34M
Enterprise Value472.51M
Income-45.00M
Sales835.41M
Book/sh10.54
Cash/sh2.13
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees1605
IPOApr 24, 1992

Ratios

P/E-
Forward P/E-
PEG-
P/S0.36
P/B0.69
P/C3.42
P/FCF-
EV/EBITDA12.53
EV/Sales0.57
Quick Ratio1.74
Current Ratio3.11
Debt/Eq0.61
LT Debt/Eq0.60
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.11
EPS next Y-0.96
EPS next Q-0.07
EPS this Y52.23%
EPS next Y13.49%
EPS next 5Y35.51%
EPS past 3/5Y-33.21% -
Sales past 3/5Y21.30% 15.13%
EPS Y/Y TTM63.59%
Sales Y/Y TTM2.12%
EPS Q/Q74.27%
Sales Q/Q1.08%
EarningsNov 09 BMO
EPS/Sales Surpr.43.40% -1.26%

Ownership

Insider Own1.21%
Insider Trans-1.09%
Inst Own94.98%
Inst Trans2.74%
ROA-5.33%
ROE-10.32%
ROIC-6.54%
Gross Margin69.44%
Oper. Margin-1.83%
Profit Margin-5.39%
SMA20-20.33%
SMA50-20.41%
SMA200-32.96%
Trades-

Technical

Shs Outstand40.75M
Shs Float40.24M
Short Float5.40%
Short Ratio4.85
Short Interest2.17M
52W High16.42 -55.57%
52W Low6.52 11.89%
Volatility13.99% 6.77%
ATR (14)0.65
RSI (14)32.77
Beta0.67
Rel Volume0.85
Avg Volume447.89K
Volume87,857

Performance

Perf Week-24.95%
Perf Month-21.22%
Perf Quarter-28.34%
Perf Half Y-40.25%
Perf YTD-51.88%
Perf Year-52.57%
Perf 3Y-27.05%
Perf 5Y-77.65%
Perf 10Y-80.30%
Recom1.50
Target Price10.00
Prev Close7.12
Price7.30
Change %2.46%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jan 27, 2026InitiatedTTD CowenHold$14+91.9%
Oct 28, 2025ResumedSStifelBuy$22+201.6%
Jan 22, 2025InitiatedCCanaccord GenuityBuy$24+229.0%
Nov 08, 2024UpgradeSStifelHold → Buy$18 → $24+229.0%
May 08, 2024UpgradeRROTH MKMNeutral → Buy$15 → $20+174.2%
Oct 20, 2023InitiatedRROTH MKMNeutral$12+64.5%
Sep 12, 2023DowngradeSStifelBuy → Hold
Sep 12, 2023DowngradeBBTIG ResearchBuy → Neutral
Jul 19, 2023ResumedBBTIG ResearchBuy$27+270.1%
Mar 04, 2022UpgradeSStifelHold → Buy$41 → $45+516.9%

Peers

Mkt cap
TickerCompanyMkt cap
ATECAlphatec Holdings Inc1.16B
GMEDGlobus Medical Inc9.91B
KIDSOrthoPediatrics corp884.36M
BVSBioventus Inc940.35M
SIBNSI-BONE Inc1.14B
XTNTXtant Medical Holdings Inc38.56M
TMCITreace Medical Concepts Inc324.85M
ZBHZimmer Biomet Holdings Inc20.20B
SIShoulder Innovations Inc451.19M
SYKStryker Corp120.84B

Insider trading

latest 14 of 33
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Fisher PatrickPresident, Global Limb ReconNov 02 '26Sale9.071501,36050,769Nov 04 04:04 PM
Fisher PatrickPresident, Global Limb ReconOct 01 '26Sale9.441501,41650,919Oct 05 04:20 PM
Fisher PatrickPresident, Global Limb ReconSep 01 '26Sale9.391501,40851,069Sep 03 04:41 PM
PATRICK FISHEROfficerSep 01 '26Proposed Sale9.394504,226Sep 01 04:40 PM
Fisher PatrickPresident, Global Limb ReconAug 18 '26Sale10.091,29513,06751,219Aug 20 05:03 PM
McPherron AvivaPres, Global Ops & QualJun 18 '26Sale9.383,67034,42566,330Jun 22 04:14 PM
HENNEMAN JOHN B IIIDirectorMay 07 '26Buy12.265,00061,29590,809May 08 04:52 PM
Engine Capital Management, LP10% OwnerMay 05 '26Buy11.99112,9501,354,5873,783,131May 07 06:15 PM
Engine Capital Management, LP10% OwnerMay 06 '26Buy12.2341,946512,9163,821,285May 07 06:15 PM
Engine Capital Management, LP10% OwnerMay 07 '26Buy12.1830,000365,4253,848,573May 07 06:15 PM
Cedron Jorge AndresCLOApr 16 '26Sale12.823,74347,98559,006Apr 20 04:11 PM
Vitale LucasCP&BOOMar 17 '26Sale11.924,26950,886160,449Mar 19 04:31 PM
CAPPS VICKIE LDirectorMar 09 '26Buy12.482,50031,20025,085Mar 10 04:13 PM
CAPPS VICKIE LDirectorMar 10 '26Buy12.452,50031,12427,585Mar 10 04:13 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
DFASU.S. Small Cap Portfolio-ETF Class Shares-
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IHIiShares U.S. Medical Devices ETFAUM: 4.07B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
DFMCU.S. Micro Cap Portfolio ETF Class Shares-

News

latest 14 of 206
  • Orthofix's EPS Beat Masks A U.S. Spine Breakdown And A Deeper Guidance Reset (Earnings Whispers)
  • Orthofix: Q3 Earnings Snapshot (Associated Press)
  • Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance (Business Wire)
  • Orthofix Faces A Clean Test Of Core Growth After A Bruising Selloff (Earnings Whispers)
  • Orthofix to Report Third Quarter 2026 Financial Results (Business Wire)
  • Loading…
  • Did Orthofix Medical Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
  • Orthofix pays former executives $24M in damages (CFO Dive)
  • Orthofix Medical Inc (OFIX) (Q2 2026) Earnings Call Highlights: Strategic Moves and Raised ... (GuruFocus.com) -14.59%
  • Orthofix: Q2 Earnings Snapshot (Associated Press)
  • Orthofix Reports Second Quarter 2026 Results Reflecting Continued Operational Progress (Business Wire)
  • Did Orthofix Medical Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
  • MedTech Pioneer Max Reinhardt Joins eXeX to Drive Canopus Platform Growth (PR Newswire)
  • Orthofix to Participate in Upcoming Investor Conferences (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.150-0.265-0.150207.86210.522
2026Q22026-08-05-0.390-0.410-0.386210.93209.282
2026Q12026-05-05-0.520-0.680-0.517196.71196.42
2025Q42026-02-24-0.060-0.190-0.056219.91218.72
2025Q32025-11-04-0.570-0.558-0.573205.63201.193
2025Q22025-08-05-0.360-0.490-0.357200.7196.194
2025Q12025-05-06-1.350-0.553-1.355193.65191.095
2024Q42025-02-25-0.750-0.293-0.753215.7212.724
2024Q32024-11-07-0.710-0.345-0.712196.61196.524
2024Q22024-08-06-0.880-0.365-0.880198.62195.224
2024Q12024-05-07-0.950-0.508-0.954188.61184.134
2023Q42024-03-05-0.5900.060-0.595200.42200.33
2023Q32023-11-080.070-0.210-0.775184.01185.84
2023Q22023-08-080.020-0.602-1.073187.02184.894
2023Q12023-05-09-0.100-0.507-1.705175.2168.463
2022Q42023-03-060.1900.340-0.350185.6144.962

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2017FY1.6201.6100.340433.82433.8
2018FY1.7901.7330.730453.04453.38
2019FY1.4701.553-1.506459.96461.45
2020FY0.260-0.0310.130406.56407
2021FY0.8600.763-1.949464.48464
2022FY0.3000.445-0.985698.24542.12
2023FY-4.120-0.179-4.122746.64746.5
2024FY-3.300-2.832-3.304799.5796.5
2025FY-2.330-2.260-2.330822.31814.43
2026FY--1.113--827.09
2027FY--0.963--819.96
2028FY--0.625--893.11

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-09404211.79211.4212.3
2026Q4S2026-10-19400233.19231.6234.05
2026Q4S2026-10-15440233.19231.6234.05
2026Q4S2026-08-28550232.75231234.05
2026Q4S2026-08-27550232.75231234.05
2026Q4S2026-08-20550232.75231234.05
2026Q4S2026-08-06550232.75231234.05
2026Q4S2026-08-05550232.75231234.05
2026Q4S2026-08-04511226.2223.8229.81
2026Q4S2026-07-02514226.2223.8229.81
2026Q4S2026-06-25505225223.8226.2
2026Q4S2026-05-21404224.83223.8226.2
2026Q4S2026-05-10501231.68229.81233.2
2026Q4S2026-05-06512231.68229.81233.2

Estimate history

EPS, annual0.340.73-1.5060.13-1.949-0.985-4.122-3.304-2.328-1.1061
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.712-0.753-1.355-0.357-0.573-0.056-0.517-0.386-0.148
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual433.823453.042459.955406.562464.479460.713746.641799.491822.312835.41
Period201720182019202020212022202320242025TTM
Sales, quarterly196.606215.657193.646203.121205.634219.911196.708210.933207.862
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual18.27918.5819.02319.42419.83720.16237.16538.48639.83440.749
Period201720182019202020212022202320242025MRQ
Shares, quarterly38.20938.48639.09639.48339.51939.83440.38240.7340.749
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue835.41822.31799.49746.64460.71464.48406.56459.95453.04
Cost of Goods Sold Incl. D&A255.33270.61271.04277.78131.74122.82108.69105.6896.63
Gross Profit580.08551.71528.45468.87328.97341.66297.87354.28356.41
Selling, General and Administrative Excl. Other595.39620.18606.17610.63357.84340.29311.44343.92319.95
Research and Development60.3765.8573.6480.2349.0749.6239.0634.6433.22
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-15.31-68.47-77.72-141.76-28.871.37-13.5710.3636.46
Interest Expense21.9917.4929.638.631.291.842.480.120.00
Unusual Expense5.2212.966.90-2.65-10.8118.74-21.1529.146.37
Net Income Before Taxes-43.27-90.81-123.88-148.68-17.71-13.50-0.37-27.0522.89
Income Taxes1.731.382.122.722.0424.88-2.891.419.07
Consolidated Net Income-45.00-92.19-126.00-151.40-19.75-38.382.52-28.4613.81
Net Income From Continuing Operations-45.00-92.19-126.00-151.40-19.75-38.382.52-28.4613.81
Net Income-45.00-92.19-126.00-151.40-19.75-38.382.52-28.4613.81
EPS (Recurring)-1.00-2.10-3.18-4.17-1.36-1.28-0.63-0.430.97
EPS (Basic, Before Extraordinaries)-1.11-2.33-3.30-4.12-0.98-1.950.13-1.510.75
EPS (Diluted)-1.11-2.33-3.30-4.12-0.98-1.950.13-1.510.73
EBITDA37.718.85-17.66-88.700.1530.9616.9835.0555.12
Non-Operating Income (Expense)-0.758.11-9.62-0.941.645.72-5.47-8.14-7.21
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense22.8223.1926.6629.9114.5711.5712.1616.1615.13
Price To Earnings Ratio------307.88-70.81
Price To Sales Ratio0.460.730.830.660.891.322.051.902.19
Gross Margin69.4467.0966.1062.8071.4173.5673.2777.0278.67
Operating Margin-1.83-8.33-9.72-18.99-6.270.29-3.342.258.05
Net Margin-5.39-11.21-15.76-20.28-4.29-8.260.62-6.193.05
Shares Outstanding40.7539.8338.4937.1620.1619.8419.4219.0218.58
Market Capitalization290.02290.02667.22495.48410.84613.88830.96879.96993.16

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue207.86210.93196.71219.91205.63203.12193.65215.66
Cost of Goods Sold Incl. D&A64.3164.2360.1666.6360.2367.4690.3871.16
Gross Profit143.55146.71136.54153.28145.40135.66103.26144.50
Selling, General and Administrative Excl. Other140.14152.89150.23152.13162.88152.43152.75155.29
Research and Development14.8114.8615.3215.3714.7715.9319.7718.81
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income3.40-6.18-13.691.15-17.47-16.77-49.48-10.79
Interest Expense5.896.095.664.354.683.954.5114.92
Unusual Expense1.861.950.750.66-0.43-0.76-0.611.10
Net Income Before Taxes-5.25-15.00-20.83-2.19-22.26-14.22-52.13-29.71
Income Taxes0.830.800.070.030.53-0.140.96-0.56
Consolidated Net Income-6.07-15.80-20.91-2.22-22.80-14.08-53.09-29.15
Net Income From Continuing Operations-6.07-15.80-20.91-2.22-22.80-14.08-53.09-29.15
Net Income-6.07-15.80-20.91-2.22-22.80-14.08-53.09-29.15
EPS (Recurring)-0.12-0.35-0.50-0.04-0.58-0.37-1.37-0.73
EPS (Basic, Before Extraordinaries)-0.15-0.39-0.52-0.06-0.57-0.36-1.35-0.75
EPS (Diluted)-0.15-0.39-0.52-0.06-0.57-0.36-1.35-0.75
EBITDA16.587.09-0.1914.23-4.530.10-15.055.21
Non-Operating Income (Expense)-0.90-0.78-0.731.67-0.545.731.25-2.91
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.336.115.166.225.676.185.115.66
Price To Sales Ratio0.460.450.560.740.710.540.790.85
Gross Margin69.0669.5569.4269.7070.7166.7953.3367.00
Operating Margin1.64-2.93-6.960.52-8.50-8.25-25.55-5.00
Net Margin-2.92-7.49-10.63-1.01-11.09-6.93-27.42-13.52
Shares Outstanding40.7540.7340.3839.8339.5239.4839.1038.49
Market Capitalization290.02369.45460.46600.33578.20436.87636.46667.22

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments85.1285.7437.7650.7087.8596.8270.4072.1981.16
Short Term Receivables135.75134.71128.1082.8678.5672.4286.8177.7563.44
Inventories172.32189.45222.17100.1582.9784.6482.4076.8581.33
Other Current Assets23.6723.3832.4222.2820.1416.5020.9517.8625.88
Total Current Assets416.85433.29420.44255.99269.52270.38260.55244.64251.80
Net Property, Plant & Equipment151.68157.04178.9365.0262.4168.4568.5342.8445.14
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Long-Term Note Receivable--0.30------
Intangible Assets267.70293.74312.42118.71123.98144.54125.32124.3064.03
Deferred Tax Assets1.881.542.081.471.7736.6747.1137.8023.32
Other Assets12.557.6911.1417.4518.9417.456.1121.6421.07
Total Assets850.65893.29925.32458.63476.62537.49507.61471.21405.35
Short Term Debt Incl. Current Port. of LT Debt3.984.785.442.294.422.602.200.000.00
Accounts Payable58.3948.8058.3627.6026.4623.1219.8917.9918.11
Income Tax Payable--------3.18
Other Current Liabilities108.11115.05101.4353.7474.9578.1862.8067.9258.12
Total Current Liabilities170.48168.63165.2283.62105.83103.9084.8885.9179.41
Long Term Debt199.86188.93128.7624.6221.3325.2824.730.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00-
Deferred Tax Liabilities6.085.644.17--11.6311.994.57-
Other Liabilities24.1826.9728.4313.5312.5339.8158.3745.3429.34
Total Liabilities400.61390.17326.59121.77139.69180.63179.98135.81108.75
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity450.04503.12598.73336.86336.93356.86327.63335.40296.61
Total Shareholders Equity450.04503.12598.73336.86336.93356.86327.63335.40296.61
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity450.04503.12598.73336.86336.93356.86327.63335.40296.61
Total Liabilities & Stockholders Equity850.65893.29925.32458.63476.62537.49507.61471.21405.35
Book Value Per Share11.3013.0716.1116.7116.9918.3717.2218.0516.23
Tangible Book Value Per Share4.585.447.7010.8210.7410.9310.6411.3612.72
Full-Time Employees1,6051,6161,6341,0921,0871,0361,055954858
Price to Book Ratio0.681.270.801.231.832.342.682.913.49
Return on Assets-10.57-13.86-21.88-4.22-7.570.48-5.823.151.88
Return on Equity-19.34-22.87-32.36-5.86-11.060.74-8.594.372.60
Return on Invested Capital-14.19-18.21-20.81-5.46-10.710.66-8.084.122.10
Quick Ratio1.431.451.201.861.761.792.101.952.15
Current Ratio2.452.572.543.062.552.603.072.853.17

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-43.36-92.19-126.00-151.40-19.75-38.382.52-28.4613.81
Depreciation52.1277.3260.0653.0629.0229.6030.5524.7018.66
Other Funds (Non Cash)60.2069.49109.09105.968.1127.4710.7263.7827.11
Funds from Operations69.7554.8445.048.2117.7043.1754.5761.4156.92
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-64.53-21.50-19.25-53.96-29.24-24.7019.70-29.38-7.00
Cash from Operating Activities5.2233.3525.79-45.75-11.5418.4874.2732.0349.92
Capital Expenditures-48.34-34.63-34.88-62.05-23.16-19.59-17.09-20.52-15.26
Net Assets From Acquisitions0.000.000.000.000.000.00-18.000.00-44.29
Sale of Fixed Assets and Businesses0.000.000.0029.420.000.000.000.00-
Purchase or Sale of Investments0.000.007.400.000.00-2.17-10.000.000.00
Purchase of Investments0.000.000.000.000.00-2.17-10.000.000.00
Sale Or Maturity of Investments0.000.007.400.000.000.000.000.000.00
Other Uses0.000.00-0.10-0.50-1.37-1.25-7.24-2.40-1.45
Other Sources0.150.030.000.00-0.000.000.000.00
Cash from Investing Activities-48.18-34.60-27.58-33.13-24.53-23.01-52.33-22.92-61.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock5.485.936.265.134.348.827.6011.557.10
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock5.485.936.265.134.348.827.6011.557.10
Proceedsfrom Stock Options5.485.936.265.134.348.827.6011.557.10
Issuance or Reduction of Debt, Net63.17-0.7654.3967.95-2.59-0.54-0.32-0.360.00
Change in Long Term Debt63.17-0.7654.3967.95-2.59-0.54-0.32-0.370.00
Issuance of Long Term Debt63.450.00197.60174.500.00-100.000.000.00
Reduction of Long Term Debt-0.27-0.76-143.21-106.55-2.59-0.54-100.32-0.370.00
Net Financing Active Other Cash Flow-3.50-5.95-9.94-7.75-1.82-11.91-4.03-21.87-4.11
Other Financing Activities Uses-3.50-5.95-9.94-7.75-1.82-11.91-4.03-21.87-4.11
Cash from Financing Activities65.15-0.7950.7165.32-0.08-3.623.25-10.692.99
Exchange Rate Effect-0.341.41-0.940.62-1.00-0.821.24-0.21-0.88
Net Change in Cash21.85-0.6247.98-12.94-37.15-8.9726.42-1.79-8.97
Free Cash Flow-43.11-1.28-9.09-106.01-32.900.6958.7913.0436.33
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow-----887.2214.1866.9627.33
Deferred Taxes & Investment Tax Credit-0.221.880.580.3124.4810.791.39-2.66

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments86.92104.41120.8785.1265.9568.69
Short Term Receivables131.72135.82137.78135.75130.81129.56
Inventories190.36184.48177.82172.32174.04172.99
Other Current Assets21.7921.4325.0623.6723.3724.59
Total Current Assets430.79446.13461.52416.85394.17395.83
Net Property, Plant & Equipment154.31153.04146.90151.68153.98154.06
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets257.84260.91264.27267.70270.58273.80
Deferred Tax Assets---1.88--
Other Assets12.8212.9513.9112.5513.8913.47
Total Assets855.76873.02886.60850.65832.61837.16
Short Term Debt Incl. Current Port. of LT Debt3.433.193.223.983.973.85
Accounts Payable58.0363.5354.6958.3950.4645.10
Other Current Liabilities76.9290.29103.12108.11105.4299.44
Total Current Liabilities138.39157.01161.03170.48159.85148.38
Long Term Debt258.65258.71259.03199.86200.51200.89
Provision for Risks Charges11.2011.000.000.000.000.00
Deferred Tax Liabilities---6.08--
Other Liabilities17.9517.1231.3524.1829.7629.54
Total Liabilities426.19443.84451.42400.61390.12378.81
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity429.57429.18435.19450.04442.49458.35
Total Shareholders Equity429.57429.18435.19450.04442.49458.35
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity429.57429.18435.19450.04442.49458.35
Total Liabilities & Stockholders Equity855.76873.02886.60850.65832.61837.16
Book Value Per Share10.5410.5410.7811.3011.2011.61
Tangible Book Value Per Share4.214.134.234.584.354.67
Full-Time Employees---1,605--
Price to Book Ratio0.680.851.021.351.260.95
Return on Assets-5.33-7.22-7.02-10.57-14.01-14.39
Return on Equity-10.32-13.91-13.43-19.34-24.60-24.63
Return on Invested Capital-0.88-2.30-3.01-0.34-3.55-2.14
Quick Ratio1.741.671.761.431.381.50
Current Ratio3.112.842.872.452.472.67

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-5.81-15.68-20.91-0.96-24.40-16.62
Depreciation12.9013.1913.4912.5413.9618.81
Other Funds (Non Cash)16.1118.7112.1013.2714.9221.32
Funds from Operations23.6916.564.7824.734.8223.08
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-23.19-22.71-22.393.758.10-11.70
Cash from Operating Activities0.50-6.15-17.6128.4812.9211.38
Capital Expenditures-14.24-12.57-10.66-10.87-10.48-7.63
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources-0.00-0.000.150.010.010.01
Cash from Investing Activities-14.24-12.57-10.52-10.86-10.46-7.62
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.022.620.002.880.063.12
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.022.620.002.880.063.12
Proceedsfrom Stock Options-0.022.620.002.880.063.12
Issuance or Reduction of Debt, Net-0.39-0.2363.99-0.20-0.20-0.20
Change in Long Term Debt-0.39-0.2363.99-0.20-0.20-0.20
Issuance of Long Term Debt-0.37-0.2164.030.000.000.00
Reduction of Long Term Debt-0.02-0.02-0.03-0.20-0.20-0.20
Net Financing Active Other Cash Flow-3.14-0.15-0.02-0.19-5.24-0.20
Other Financing Activities Uses-3.14-0.15-0.02-0.19-5.24-0.20
Cash from Financing Activities-3.552.2463.972.50-5.372.72
Exchange Rate Effect-0.15-0.04-0.09-0.06-0.091.11
Net Change in Cash-17.44-16.5335.7620.06-3.017.59
Free Cash Flow-13.74-18.72-28.2717.612.443.75

Revenue breakdown

Brazil2024: 5.71M 2025: 4.84M
France2024: 13.39M 2025: 11.96M
Germany2024: 9.00M 2025: 9.11M
Italy2024: 21.00M 2025: 22.28M
Other Countries2024: 66.40M 2025: 76.73M
United Kingdom2024: 11.18M 2025: 13.33M
United States2024: 672.82M 2025: 684.07M
Global Limb Reconstruction2024: 124.18M 2025: 134.66M
Global Spine2024: 675.31M 2025: 687.66M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.40%2.2M40.2M386.04K
2026-10-155.94%2.4M40.2M374.40K
2026-09-306.07%2.4M40.2M372.40K
2026-09-156.23%2.5M40.2M369.21K
2026-08-315.91%2.4M40.2M381.71K
2026-08-145.15%2.1M40.3M438.27K
2026-07-315.27%2.1M40.3M424.03K
2026-07-156.28%2.5M40.0M413.01K
2026-06-305.91%2.4M40.0M385.22K
2026-06-154.98%2.0M40.0M359.97K
2026-05-294.87%2.0M40.1M339.71K
2026-05-153.31%1.3M39.2M297.01K
2026-04-303.16%1.2M39.2M270.32K
2026-04-153.43%1.3M38.9M269.45K
2026-03-313.05%1.2M39.3M265.63K
2026-03-132.73%1.1M39.3M248.82K
2026-02-272.80%1.1M39.3M224.71K
2026-02-132.67%1.1M39.3M214.46K
2026-01-302.60%1.0M38.8M224.00K
2026-01-152.75%1.1M38.8M228.24K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.502.656.609.7217.9341.000.000.931-0.0920.002
call5.000.154.200.008.2870.000.000.806-0.0900.003
call7.500.001.553.403.5832.000.000.571-0.0750.005
call10.000.001.750.053.33517.000.000.370-0.0800.004
call12.500.000.200.052.70352.000.000.148-0.0370.003
call15.000.001.950.053.28412.000.000.130-0.0440.002
call17.500.002.150.603.7451.000.000.119-0.0470.002
call20.000.002.150.004.1260.000.000.111-0.0500.002
call22.500.002.000.004.4510.000.000.106-0.0520.002
put2.500.002.150.009.4220.000.00-0.071-0.0810.002
put5.000.002.000.004.4070.000.00-0.186-0.0740.003
put7.500.001.000.901.8801280.00-0.444-0.0690.005
put10.000.904.801.556.50444.000.00-0.523-0.1180.005
put12.503.407.300.007.6890.000.00-0.852-0.0390.003
put15.005.909.800.008.4020.000.00-0.870-0.0430.002
put17.508.4012.300.008.9680.000.00-0.881-0.0450.002
put20.0010.9014.800.009.4350.000.00-0.888-0.0480.002
put22.5013.4017.3010.269.8310.000.00-0.894-0.0490.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-234/A2026-09-18SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-028-KCurrent report2026-07-01SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-118-KCurrent report2026-06-11SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-22SEC
2026-05-293Initial statement of beneficial ownership of securities2026-05-21SEC
2026-05-29SDSpecialized Disclosure ReportSEC
2026-05-27SCHEDULE 13D/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11001.36K1
2026-10001.42K1
2026-09001.41K1
2026-080013.07K1
2026-070000
2026-060034.42K1
2026-052.29M400
2026-040047.99K1
2026-0362.32K2411.61K15
2026-021.73M200
2026-0100371.03K3
2025-120000
2025-110000

Institutional holders

Manager% owned
Engine Capital Management, LP11.32%
Juniper Investment Company, LLC10.99%
Rubric Capital Management LP9.21%
BlackRock, Inc.8.23%
PARADIGM CAPITAL MANAGEMENT INC/NY8.17%
ARMISTICE CAPITAL, LLC8.07%
VANGUARD CAPITAL MANAGEMENT LLC4.28%
STATE STREET CORP2.36%
GEODE CAPITAL MANAGEMENT, LLC2.27%
AQR CAPITAL MANAGEMENT LLC2.20%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.01%
iShares Russell 2000 ETF2.55%
VANGUARD EXTENDED MARKET INDEX FUND1.17%
Fidelity Small Cap Index Fund1.09%
Paradigm Micro-Cap Fund0.99%
iShares Russell 2000 Value ETF0.86%
VANGUARD RUSSELL 2000 INDEX FUND0.57%
Schwab U.S. Small-Cap ETF0.48%
iShares U.S. Medical Devices ETF0.47%
1290 VT GAMCO Small Company Value Portfolio0.46%

OakChart. OFIX. Cached 15 minutes.